Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Redhill Biophrma ADR (NQ: RDHL ) 0.3211 +0.0310 (+10.69%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Redhill Biophrma ADR < Previous 1 2 3 4 5 6 7 8 9 10 Next > The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO August 26, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... Via Benzinga Exposures COVID-19 12 Health Care Stocks Moving In Thursday's Pre-Market Session August 26, 2021 Gainers Ascendis Pharma (NASDAQ:ASND) stock increased by 22.69% to $151.73 during Thursday's pre-market session. The company's market cap stands at $8.1 billion.... Via Benzinga Redhill Biopharma: Q2 Earnings Insights August 26, 2021 Shares of Redhill Biopharma (NASDAQ:RDHL) rose 11.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 250.00%... Via Benzinga Why Redhill Biopharma's Stock Is Trading Higher Today May 18, 2021 Redhill Biopharma (NASDAQ:RDHL) shares are tradi... Via Benzinga RedHill Reports Second Quarter 2021 Results August 26, 2021 - Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 -... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Supply Chain Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition August 26, 2021 RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model,... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Earnings Scheduled For August 26, 2021 August 26, 2021 Companies Reporting Before The Bell • Gambling.com Gr (NASDAQ:GAMB) is likely to report quarterly earnings at $0.07 per share on revenue of $10.38 million. •... Via Benzinga A Preview Of Redhill Biopharma's Earnings August 25, 2021 Redhill Biopharma (NASDAQ:RDHL) will be releasing its next round of earnings this Thursday, August 26. For all of the relevant information, here is your guide for Thursday's Q2... Via Benzinga RedHill Announces Two New U.S. Patents August 23, 2021 RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs July 30, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Exposures Product Safety RedHill Extends Talicia Commercial Coverage July 20, 2021 RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx Addition of Talicia® by OptumRx significantly extends Commercial patient access to Talicia® through... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out July 19, 2021 RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19... From RedHill Biopharma Ltd Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Benzinga's Top Ratings Upgrades, Downgrades For May 28, 2021 May 28, 2021 Upgrades For Delek US Holdings Inc (NYSE:DK), Tudor Pickering upgraded the previous rating of Hold to Buy. For the first quarter, Delek US Hldgs had an EPS of $1.69,... Via Benzinga 35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021 May 27, 2021 RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be... From MicroCap Rodeo Via AccessWire Redhill Biopharma: Q1 Earnings Insights May 27, 2021 Shares of Redhill Biopharma (NASDAQ:RDHL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were flat 0.00% year over year to ($0.... Via Benzinga Earnings Outlook for Redhill Biopharma May 26, 2021 Redhill Biopharma (NASDAQ:RDHL) releases its next round of earnings this Thursday, May 27. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings... Via Benzinga RedHill's Novel Late-Stage Pills Hold Promise Against COVID-19 and its Variants May 25, 2021 Photo by Elsa Olofsson on Unsplash World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus recently said the COVID-19 pandemic's second year was on track to be... Via Benzinga Exposures COVID-19 The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs May 27, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... Via Benzinga Exposures COVID-19 Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 May 18, 2021 Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,... Via Benzinga Earnings Scheduled For May 27, 2021 May 27, 2021 Companies Reporting Before The Bell • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.48 per share on revenue of $11.77 billion. •... Via Benzinga The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron May 12, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... Via Benzinga Exposures COVID-19 Stocks That Hit 52-Week Lows On Tuesday May 11, 2021 Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW... Via Benzinga The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings May 11, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... Via Benzinga Exposures COVID-19 Product Safety Stocks That Hit 52-Week Lows On Monday May 10, 2021 Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT).... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.